Sanofi halts development of its OX40‑ligand antibody amlitelimab for atopic dermatitis, ending a key immuno‑inflammation program
Executive summary: Sanofi discontinued clinical development of amlitelimab for atopic dermatitis and will not seek regulatory approval. The halt ends a promising immuno‑inflammation asset, affecting Sanofi’s pipeline and altering competitive dynamics in the atopic dermatitis biologic market.
Who is involved: Sanofi (drug developer), clinical trial investigators, and patients enrolled in amlitelimab studies.
Likely next: Sanofi will redirect resources to other immuno‑modulator projects; competitors may accelerate their OX40‑targeted assets to capture the vacated space.
Sanofi announced on July 24, 2026 that it will stop clinical development of amlitelimab, an OX40‑ligand monoclonal antibody, in moderate‑to‑severe atopic dermatitis. The decision follows a review of the drug’s clinical profile and market landscape, and means the compound will not proceed to global regulatory submissions. This move frees up R&D resources but removes Sanofi from a competitive class of biologics targeting the OX40 pathway, a space where rivals have ongoing programs.
Timeline
- — Press Release: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews (GlobeNewswire)
Key entities
Sources
- Press Release: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews — GlobeNewswire